Cordis Europe Signs Agreement with Volcano Europe to Provide Access to State-of-the-Art Intravascular Imaging for Use in Drug-Eluting Stent Procedures
Share:
WATERLOO, Belgium, November 8 Collaboration Focuses on Providing the Benefits of IVUS-Guided Stenting to a Wider Array of Hospitals
Cordis Europe announced today a collaboration with Volcano
Europe, a developer and manufacturer of intravascular ultrasound (IVUS)
systems and imaging catheters, that will allow Cordis to assist hospitals in
Europe to gain access to Volcano's state-of-the-art IVUS technology.
IVUS is a catheter-based imaging system that allows physicians
to acquire very high-resolution images of diseased vessels from inside the
artery and facilitates more accurate stent placement.
"Cordis is determined to make IVUS technology more widely
available to European physicians and their patients with coronary artery
disease," stated Staffan Ternstrom, President, Cordis Europe, Middle East and
Africa. "More than three million patients worldwide have received the
CYPHER® Sirolimus-eluting Coronary Stent, whose safety and efficacy is
supported by a robust clinical trial program that includes more than 75
clinical studies. Now, along with IVUS, physicians have a new and innovative
tool to treat the many patients in Europe with coronary artery disease."
In the past, doctors have used angiograms as a guide to
appropriately deploy a stent but as IVUS has improved, doctors and patients
are beginning to recognize the advantages of a well-visualized stent
placement, particularly in complex lesions. Several recent studies have
highlighted the value of IVUS guided stenting for optimal procedural
outcomes.
About the CYPHER® Stent
The CYPHER® Stent is the most studied drug-eluting stent in
history and has been chosen by cardiologists worldwide to treat more than 3
million patients with coronary artery disease. The safety and efficacy of the
device is supported by a robust clinical trial program that includes more
than 70 studies that examine the performance of the CYPHER® Stent in a
broad range of patients.
The CYPHER® Stent is currently available in more than 80
countries and has the broadest clinical experience and longest-term clinical
follow-up of any drug-eluting stent. The next version of a sirolimus-eluting
stent, the CYPHER SELECT(TM) Sirolimus-eluting Coronary Stent, was launched
in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER
SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary
stent, received CE Mark in 2006 and is currently available in many markets
outside the United States.
About Cordis Corporation
Cordis, a Johnson & Johnson company, is a worldwide leader in
the development and manufacture of interventional vascular technology.
Through the company's innovation, research and development, Cordis partners
with interventional cardiologists worldwide to treat millions of patients who
suffer from vascular disease.
Cordis Corporation has entered into an exclusive worldwide
license with Wyeth for the localized delivery of sirolimus in certain fields
of use, including delivery via vascular stenting. Sirolimus, the active drug
released for the stent, is marketed by Wyeth Pharmaceuticals, a division of
Wyeth, under the name Rapamune® .
Source: Cordis Corporation
Media Contact: Teresa M. Mueller
Office : +33-1-5500-4433
tmueller1@jnjfr.jnj.com
